Frequencies of CD33+CD11b+HLA-DR–CD14–CD66b+ and CD33+CD11b+HLA-DR–CD14+CD66b– Cells in Peripheral Blood as Severity Immune Biomarkers in COVID-19
Ricardo Wesley Alberca, Milena Mary de Souza Andrade, Anna Cláudia Calvielli Castelo Branco, Anna Julia Pietrobon, Nátalli Zanete Pereira, Iara Grigoletto Fernandes, Luana de Mendonça Oliveira, Franciane Mouradian Emidio Teixeira, Danielle Rosa Beserra, Emily Araujo de Oliveira, Sarah Cristina Gozzi-Silva, Yasmim Álefe Leuzzi Ramos, Cyro Alves de Brito, Marcelo Arnone, Raquel Leão Orfali, Valéria Aoki, Alberto José da Silva Duarte, Maria Notomi Sato
Abstract
Common clinical features of patients with Coronavirus disease-2019 (COVID-19) vary from fever, to acute severe respiratory distress syndrome. Several laboratory parameters are reported as indicators of COVID-19 severity. We hereby describe a possible novel severity biomarker for COVID-19, characterized as a population of CD11b+CD33+HLA- cells, that can be further divided into CD14+ mononuclear cells and CD66b+ polymorphonuclear cells.